Identifying patients at risk for severe side effects from immune checkpoint inhibitors in melanoma treatment
Project 3
This study is looking to make melanoma treatment safer and more effective by finding out which patients might experience serious side effects from immune checkpoint inhibitors, using a simple blood test to check for certain autoantibodies, so that doctors can tailor treatments to help you get the most benefit with fewer risks.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11196469 on NIH RePORTER |
What this research studies
This research focuses on improving the safety and effectiveness of immune checkpoint inhibitors (ICIs) used in melanoma treatment. It aims to identify patients who are at risk of developing severe immune-related adverse events (irAEs) due to ICI therapy by analyzing specific pre-existing autoantibodies in their blood. By developing a predictive tool based on these biomarkers, the research seeks to optimize treatment plans and minimize the risk of severe side effects while maximizing the therapeutic benefits of ICIs. This approach could lead to better management of treatment-related toxicities and improved patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who are about to begin treatment with immune checkpoint inhibitors.
Not a fit: Patients who are not undergoing treatment with immune checkpoint inhibitors or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help clinicians tailor melanoma treatments to individual patients, reducing the risk of severe side effects and enhancing the overall effectiveness of therapy.
How similar studies have performed: While there is ongoing interest in identifying biomarkers for predicting responses to immune checkpoint inhibitors, this specific approach to predicting irAEs is novel and has not been extensively tested.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Krogsgaard, Michelle — New York University School of Medicine
- Study coordinator: Krogsgaard, Michelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.